Search

Your search keyword '"Fabbro, Michel"' showing total 537 results
Start Over Author "Fabbro, Michel"
537 results on '"Fabbro, Michel"'

1. The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research

Author

Moniot, Aurélie, Schneider, Christophe, Chardin, Laure, Yaniz-Galende, Elisa, Genestie, Catherine, Etiennot, Marion, Henry, Aubéri, Drelon, Coralie, Le Formal, Audrey, Langlois, Benoit, Venat, Laurence, Louvet, Christophe, Favier, Laure, Lortholary, Alain, Berton-Rigaud, Dominique, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Dubot, Coraline, Kurtz, Jean Emmanuel, Bonichon Lamichhane, Nathalie, Pujade-Lauraine, Éric, Jeanne, Albin, Leary, Alexandra, and Dedieu, Stéphane

Published
2024
Full Text
View/download PDF

4. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

Author

González-Martín, Antonio, Rubio, María Jesús, Heitz, Florian, Depont Christensen, René, Colombo, Nicoletta, Van Gorp, Toon, Romeo, Margarita, Ray-Coquard, Isabelle, Gaba, Lydia, Leary, Alexandra, De Sande, Luis Miguel, Lebreton, Coriolan, Redondo, Andrés, Fabbro, Michel, Barretina Ginesta, Maria-Pilar, Follana, Philippe, Pérez-Fidalgo, J. Alejandro, Rodrigues, Manuel, Santaballa, Ana, Sabatier, Renaud, Bermejo-Pérez, Maria José, Lotz, Jean-Pierre, Pardo, Beatriz, Marquina, Gloria, Sánchez-Lorenzo, Luisa, Quindós, María, Estévez-García, Purificación, Guerra Alía, Eva, Manso, Luis, Casado, Victoria, Kommoss, Stefan, Tognon, Germana, Henry, Stéphanie, Bruchim, Ilan, Oaknin, Ana, and Selle, Frédéric

Published
2024
Full Text
View/download PDF

5. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Author

Bogner, Gerhard, Marth, Christian, Petru, Edgar, Reinthaller, Alexander, Schauer, Christian, Sevelda, Paul, D’Hondt, Lionel, Vergote, Ignace, Vuylsteke, Peter, Hietanen, Sakari, Lindahl, Gabriel, Mäenpää, Johanna, Nøttrup, Trine Jakobi, Puistola, Ulla, Abadie-Lacourtoisie, Sophie, Alexandre, Jérôme, Berton-Rigaud, Dominique, Boissier, Emilie, Bourgeois, Hugues, Chevalier-Place, Annick, Combe, Pierre, Costan, Cristina, Dauba, Jérôme, De Cock, Laure, Desauw, Christophe, Despax, Raymond, Dohollou, Nadine, Dubot, Coraline, Fabbro, Michel, Favier, Laure, Floquet, Anne, Follana, Philippe, Tixidre, Claire Garnier, Garnier, Georges, Gladieff, Laurence, Grenier, Julien, Guillemet, Cécile, Hardy-Bessard, Anne-Claire, Joly, Florence, Kalbacher, Elsa, Kaminsky, Marie-Christine, Kurtz, Jean-Emmanuel, Largillier, Rémy, Lefeuvre-Plesse, Claudia, Lesoin, Anne, Levache, Charles Briac, L’Haridon, Tifenn, Lortholary, Alain, Lotz, Jean-Pierre, Medioni, Jacques, Meunier, Jérôme, Mousseau, Mirerille, Mouret-Reynier, Marie-Ange, Pautier, Patricia, Petit, Thierry, Provansal, Magali, Pujade-Lauraine, Eric, Raban, Nadia, Ray-Coquard, Isabelle, Rodrigues, Manuel, Selle, Frédéric, Sverdlin, Robert, Tazi, Youssef, You, Benoît, Aktas, Bahriye, Olaf Bauerschlag, Dirk, Beck, Thomas, Belau, Antje, Bronger, Holger, Buchholz, Stefan, Buderath, Paul, Burges, Alexander, Canzler, Ulrich, de Gregorio, Nikolaus, Denschlag, Dominik, Dieterich, Max, Eichbaum, Michael, El-Balat, Ahmed, Emons, Günter, Fasching, Peter, Feisel-Schwickardi, Gabriele, Frank, Matthias, Friedrich, Michael, Grischke, Eva-Maria, Gropp-Meier, Martina, Hanker, Lars, Hannig, Carla, Harter, Philipp, Hasenburg, Annette, Hellriegel, Martin, Herwig, Uwe, Heubner, Martin, Hulde, Joachim, Jackisch, Christian, Kögel, Matthias, Krieger, Peter, Kühn, Thorsten, Liebrich, Clemens, Lück, HansJoachim, Mallmann, Peter, Marmé, Frederik, Meier, Werner, Möbus, Voker, Mohamed, Omar Farag, Nestle-Krämling, Carolin, Neunhöffer, Tanja, Oskay-Özcelik, Gülten, Park-Simon, Tjoung-Won, Rautenberg, Beate, Rein, Daniel, Ruhwedel, Wencke, Runnebaum, Ingo, Sagasser, Jacqueline, Schmalfeldt, Barbara, Schneeweiss, Andreas, Schnelzer, Andreas, Scholz, Heinz, Sehouli, Jalid, Sperfeld, Antje, Steckkönig, Annette, Strauß, Hans-Georg, Tomé, Oliver, Treustedt, Jörn, Voß, Hermann, Wischnik, Arthur, Witteler, Ralf, Wöckel, Achim, Woeltjen, Hans-Heinrich, Zorr, Andreas, Bologna, Alessandra, Colombo, Nicoletta, Tognon, Germana, Cinieri, Saverio, Lorusso, Domenica, Mosconi, Anna Maria, Pignata, Sandro, Savarese, Antonella, Scambia, Giovanni, Sorio, Roberto, Zamagni, Claudio, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Kobayashi, Hiroaki, Matsumoto, Takashi, Nagao, Shoji, Satoh, Toyomi, Yonemori, Kan, Yoshida, Hiroyuki, Bratos, Raquel, Caballero, Cristina, Garica, Yolanda, González-Martín, Antonio, Guerra-Alía, Eva Maria, Hernando, Susana, Herrero, Ana, Lainez, Nuria, Manso, Luis, Martin, Cristina, Murata, Eleonor, Ortega, Eugenia, Palacio, Isabel, Poveda, Andres, Romero, Ignacio, Rubio-Pérez, María Jesús, Harter, P., Marth, C., Mouret-Reynier, M.-A., Cropet, C., Lorusso, D., Guerra-Alía, E.M., Matsumoto, T., Vergote, I., Colombo, N., Mäenpää, J., Lebreton, C., de Gregorio, N., Mosconi, A.M., Rubio-Pérez, M.J., Bourgeois, H., Fasching, P.A., Cecere, S.C., Hardy-Bessard, A.-C., Denschlag, D., de Percin, S., Hanker, L., Favier, L., Bauerschlag, D., Desauw, C., Hillemanns, P., Largillier, R., Sehouli, J., Grenier, J., Pujade-Lauraine, E., and Ray-Coquard, I.

Published
2025
Full Text
View/download PDF

7. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

Author

Monk, Bradley J., Romero, Ignacio, Graybill, Whitney, Churruca, Cristina, O'Malley, David M., Knudsen, Anja Ør, Yap, Oi Wah Stephanie, Baurain, Jean-François, Rose, Peter G., Denys, Hannelore, Ghamande, Sharad, Pisano, Carmela, Fabbro, Michel, Braicu, Elena Ioana, Calvert, Paula M., Amit, Amnon, Prendergast, Emily, Taylor, Adekemi, Kheibarshekan, Leila, Zhang, Zhi-Yi, Zajic, Stefan, Jewell, Roxanne C., Gupta, Divya, and González-Martín, Antonio

Published
2024
Full Text
View/download PDF

8. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Author

Lorusso, Domenica, Mouret-Reynier, Marie-Ange, Harter, Philipp, Cropet, Claire, Caballero, Cristina, Wolfrum-Ristau, Pia, Satoh, Toyomi, Vergote, Ignace, Parma, Gabriella, Nøttrup, Trine J, Lebreton, Coriolan, Fasching, Peter A, Pisano, Carmela, Manso, Luis, Bourgeois, Hugues, Runnebaum, Ingo, Zamagni, Claudio, Hardy-Bessard, Anne-Claire, Schnelzer, Andreas, Fabbro, Michel, Schmalfeldt, Barbara, Berton, Dominique, Belau, Antje, Lotz, Jean-Pierre, Gropp-Meier, Martina, Gladieff, Laurence, Lück, Hans-Joachim, Abadie-Lacourtoisie, Sophie, Pujade-Lauraine, Eric, and Ray-Coquard, Isabelle

Published
2024
Full Text
View/download PDF

9. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

10. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer

Author

Blanc-Durand, Félix, Yaniz-Galende, Elisa, Llop-Guevara, Alba, Genestie, Catherine, Serra, Violeta, Herencia-Ropero, Andrea, Klein, Christophe, Berton, Dominique, Lortholary, Alain, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Bonichon-Lamaichhane, Nathalie, Dubot, Coraline, Kurtz, Jean Emmanuel, de Rauglaudre, Gaëtan, Raban, Nadia, Chevalier-Place, Annick, Ferron, Gwenael, Kaminsky, Marie-Christine, Kramer, Claire, Rouleau, Etienne, and Leary, Alexandra

Published
2023
Full Text
View/download PDF

11. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial

Author

Ferron, Gwénaël, De Rauglaudre, Gaëtan, Becourt, Stéphanie, Delanoy, Nicolas, Joly, Florence, Lortholary, Alain, You, Benoît, Bouchaert, Patrick, Malaurie, Emmanuelle, Gouy, Sebastien, Kaminsky, Marie-Christine, Meunier, Jérôme, Alexandre, Jérôme, Berton, Dominique, Dohollou, Nadine, Dubot, Coraline, Floquet, Anne, Favier, Laure, Venat-Bouvet, Laurence, Fabbro, Michel, Louvet, Christophe, Lotz, Jean-Pierre, Abadie-Lacourtoisie, Sophie, Desauw, Christophe, Del Piano, Francesco, Leheurteur, Marianne, Bonichon-Lamichhane, Nathalie, Rastkhah, Mansour, Follana, Philippe, Gantzer, Justine, Ray-Coquard, Isabelle, and Pujade-Lauraine, Eric

Published
2023
Full Text
View/download PDF

12. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma

Author

Colomba, Emeline, Alexandre, Jérôme, Le Teuff, Gwénaël, Genestie, Catherine, Coupez, Dahna, Coquard, Isabelle Ray, Brachet, Pierre Emmanuel, de Percin, Sixtine, Sajous, Christophe, Fabbro, Michel, Delanoy, Nicolas, Joly, Florence, Frenel, Jean Sebastien, Pautier, Patricia, and Leary, Alexandra

Published
2023
Full Text
View/download PDF

13. Gestion pratique des inhibiteurs de PARP : Un consensus national DELPHI

Author

Selle, Frédéric, Boffa, Jean-Jacques, Etienne, Gabriel, Angelergues, Antoine, Augereau, Paule, Berton, Dominique, Dielenseger, Pascale, Fabbro, Michel, Falandry, Claire, Follana, Philippe, Gladieff, Laurence, Joly, Florence, Kurtz, Jean-Emmanuel, Matta, Carla, Mouret-Reynier, Marie-Ange, Schmitt, Antonin, Scotté, Florian, Marjollet, Coralie, and Floquet, Anne

Published
2022
Full Text
View/download PDF

14. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study

Author

Joly, Florence, Fabbro, Michel, Berton, Dominique, Lequesne, Justine, Anota, Amélie, Puszkiel, Alicja, Floquet, Anne, Vegas, Hélène, Bourgeois, Hugues, Bengrine Lefevre, Leïla, You, Benoît, Pommeret, Fanny, Lortholary, Alain, Spaeth, Dominique, Hardy-Bessard, Anne-Claire, Abdeddaim, Cyril, Kaminsky-Forrett, Marie-Christine, Tod, Michel, Kurtz, Jean-Emmanuel, Del Piano, Francesco, Meunier, Jérôme, Raban, Nadia, Alexandre, Jérome, Mouret-Reynier, Marie-Ange, Ray-Coquard, Isabelle, Provansal Gross, Magali, and Brachet, Pierre-Emmanuel

Published
2022
Full Text
View/download PDF

15. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

Author

Schenone, Laurence, Houillier, Caroline, Tanguy, Marie Laure, Choquet, Sylvain, Agbetiafa, Kossi, Ghesquières, Hervé, Damaj, Gandhi, Schmitt, Anna, Bouabdallah, Krimo, Ahle, Guido, Gressin, Remy, Cornillon, Jérôme, Houot, Roch, Marolleau, Jean-Pierre, Fornecker, Luc-Matthieu, Chinot, Olivier, Peyrade, Frédéric, Bouabdallah, Reda, Moluçon-Chabrot, Cécile, Gyan, Emmanuel, Chauchet, Adrien, Casasnovas, Olivier, Oberic, Lucie, Delwail, Vincent, Abraham, Julie, Roland, Virginie, Waultier-Rascalou, Agathe, Willems, Lise, Morschhauser, Franck, Fabbro, Michel, Ursu, Renata, Thieblemont, Catherine, Jardin, Fabrice, Tempescul, Adrian, Malaise, Denis, Touitou, Valérie, Nichelli, Lucia, Le Garff-Tavernier, Magali, Plessier, Aurélie, Bourget, Philippe, Bonmati, Caroline, Wantz-Mézières, Sophie, Giordan, Quentin, Dorvaux, Véronique, Charron, Cyril, Jabeur, Waliyde, Hoang-Xuan, Khê, Taillandier, Luc, and Soussain, Carole

Published
2022
Full Text
View/download PDF

16. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study

Author

Lesueur, Paul, Damaj, Gandhi, Hoang-Xuan, Khê, Roland, Virginie, Schmitt, Anna, Chinot, Olivier, Fabbro, Michel, Agapé, Philippe, Moluçon-Chabrot, Cécile, Chebrek, Safia, Alentorn, Agusti, Feuvret, Loic, Delgadillo, Daniel, Stefan, Dinu, Choquet, Sylvain, Nichelli, Lucia, Mokhtari, Karima, Mathon, Bertrand, Dureau, Sylvain, Soussain, Carole, and Houillier, Caroline

Published
2022
Full Text
View/download PDF

17. TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Author

Kabirian, Rayan, Tredan, Olivier, Marmé, Frederik, Paoletti, Xavier, Eberst, Lauriane, Lebreton, Coriolan, De La Motte Rouge, Thibault, Sabatier, Renaud, Angelergues, Antoine, Fabbro, Michel, Van Gorp, Toon, Mansi, Laura, Gladieff, Laurence, Kaczmarek, Emilie, Alexandre, Jérôme, Grellety, Thomas, Favier, Laure, Welz, Julia, Frenel, Jean-Sébastien, and Leary, Alexandra

Abstract

Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy. Clinical Trial Registration:NCT04713514 (ClinicalTrials.gov) Tweetable Abstract Ongoing Phase II study randomizing vaccine OSE2101 +/- Pembrolizumab vs supportive care as maintenance in platinum-sensitive recurrent ovarian cancer. Plain Language Summary Phase II study evaluating vaccine OSE2101 +/- Pembrolizumab vs supportive care as maintenance in patients with recurrent platinum-sensitive ovarian cancer. Ovarian cancer often becomes a long-term condition that needs ongoing treatment. After chemotherapy, women usually receive additional treatments to keep the cancer under control. There are only two approved treatments for this: bevacizumab administered every 3 weeks, and poly ADP-ribose polymerase inhibitors (PARP) inhibitors, which are pills that women can take if their cancer responds to platinum-based chemotherapy. However, if women have already been treated with both bevacizumab and a PARP inhibitor, there are no approved options left to maintain control of the cancer after chemotherapy. A new potential treatment, called OSE2101, is being studied: it is a vaccine designed to activate the body's immune cells to fight against cancer. The TEDOVA study is looking at how well this vaccine works in women with ovarian cancer who have already been treated with both bevacizumab and a PARP inhibitor and whose cancer is responding to platinum-based chemotherapy again. Participants are randomly assigned to one of three groups after their chemotherapy: standard supportive care, OSE2101 vaccine alone and the combination of OSE2101 vaccine with pembrolizumab. The goal of the TEDOVA study is to see if the combination of the OSE2101 vaccine and pembrolizumab can better control the cancer and to make sure the treatments are safe. The study is being run by ARCAGY-GINECO and is currently recruiting patients in France, Germany and Belgium. The study will continue to accept new patients until the end of 2024, and it is registered on ClinicalTrial.gov under the number NCT04713514. Article highlights Advanced epithelial ovarian cancer Most patients diagnosed with ovarian cancer (OC) have no evidence of disease after standard treatment with debulking surgery and platinum-based chemotherapy. Long-term survival depends on the recurrence of the disease, the delay between the last platinum-based chemotherapy defining the platinum-sensibility which is a major prognostic factor. Study rationale Women with platinum-sensible relapse (more than 6 months after the last platinum received) will be managed as patients with a chronic disease requiring iterative lines of platinum-based chemotherapy. After several cycles of treatment, chemotherapy is usually stopped and one of the major priorities is to extend platinum-free interval proposing maintenance strategies, as targeted therapy bevacizumab or poly ADP-ribose polymerase inhibitors (PARPi). When those lines of therapy have been received during previously, they cannot be reuse. That is the reason of developing new therapies and associations as maintenance therapy. TEDOVA study TEDOVA is a Phase II, randomized, open-label, multicenter study assessing the efficacy of vaccine OSE2101 + anti PD-1 pembrolizumab as maintenance therapy in women with platinum-sensible relapse of OC. We included women with HLA-A2 phenotype (~45% of the general population) with platinum sensitive OC regardless of the number of prior lines of platinum-based chemotherapy. Patients must have been previously treated with bevacizumab and a PARPi, or have a contra-indication. End points The primary end point is to evaluate the progression free survival of maintenance OSE2101 alone or in combination with PD1 inhibitor. The secondary end points are to compare the best overall response rate for patients with measurable disease at randomization, the safety and tolerability, the time to subsequent first and second treatments and the overall survival. Key eligibility Eligible patients were aged ≥18 years of age with histologically proven non-mucinous epithelial OC, positive HLA-A2 phenotype, and platinum sensitive OC regardless of the number of prior lines of platinum-based chemotherapy. Patients must have been previously treated with bevacizumab and a PARPi, or have a contraindication. Study procedures A total of 180 patients with an HLA-A2 positive phenotype will be randomized into three study arms in a 1:1:2 ratio: Arm A (n = 45) will receive observation/best supportive care, Arm B (n = 45) will receive OSE2101 and Arm C (n = 90) will receive OSE2101 plus pembrolizumab. Patients will be followed until disease progression, intolerance, withdrawal of consent, or for up to 2 years. Statistics One-sided log-rank tests will be conducted in a predefined sequence: H1: Compare Arm C (OSE2101 + pembrolizumab) with Arm A (best supportive care). If H1 shows a statistically significant difference, then proceed to: H2: Compare Arm C (OSE2101 + pembrolizumab) with Arm B (OSE2101). If both H1 and H2 show statistically significant differences, then proceed to: H3: Compare Arm B (OSE2101) with Arm A (best supportive care). A total of 121 events (progressions or deaths) is required to perform the first test of H1. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study

Author

Joly, Florence, Fabbro, Michel, Follana, Philippe, Lequesne, Justine, Medioni, Jacques, Lesoin, Anne, Frenel, Jean-Sébastien, Abadie-Lacourtoisie, Sophie, Floquet, Anne, Gladieff, Laurence, You, Benoît, Gavoille, Céline, Kalbacher, Elsa, Briand, Mélanie, Brachet, Pierre-Emmanuel, Giffard, Florence, Weiswald, Louis-Bastien, Just, Pierre-Alexandre, Blanc-Fournier, Cécile, Leconte, Alexandra, Clarisse, Bénédicte, Leary, Alexandra, and Poulain, Laurent

Published
2022
Full Text
View/download PDF

19. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Author

Harter, Philipp, Mouret-Reynier, Marie Ange, Pignata, Sandro, Cropet, Claire, González-Martín, Antonio, Bogner, Gerhard, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Nøttrup, Trine Jakobi, Floquet, Anne, El-Balat, Ahmed, Scambia, Giovanni, Guerra Alia, Eva Maria, Fabbro, Michel, Schmalfeldt, Barbara, Hardy-Bessard, Anne-Claire, Runnebaum, Ingo, Pujade-Lauraine, Eric, and Ray-Coquard, Isabelle

Published
2022
Full Text
View/download PDF

21. Longitudinal assessment of quality of life, neurocognition and psychopathology in patients with low-grade glioma on first-line temozolomide: a feasibility study

Author

Darlix, Amélie, primary, Monnier, Maëlle, additional, Castan, Florence, additional, Coutant, Louise, additional, Fabbro, Michel, additional, Denis, Ève, additional, Carriere, Mathilde, additional, Menjot-de-Champfleur, Nicolas, additional, Rigau, Valérie, additional, Duffau, Hugues, additional, and Guerdoux, Estelle, additional

Published
2024
Full Text
View/download PDF

22. Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT)

Author

Blanc-Durand, Félix, Lefeuvre-Plesse, Claudia, Ray-Coquard, Isabelle, Chaltiel, Dan, Floquet, Anne, Meriaux, Émeline, Berton, Dominique, Bello-Roufai, Diana, Guillemet, Cécile, Dupre, Pierre-François, Faller, Émilie, Alexandre, Jérôme, Hardy-Bressard, Anne-Claire, Collard, Olivier, Fabbro, Michel, Provansal, Magali, Kalbacher, Elsa, Genestie, Catherine, and Pautier, Patricia

Published
2020
Full Text
View/download PDF

24. Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy

Author

Yaniz-Galende, Elisa, primary, Zeng, Qinghe, additional, Grau-Bejar, Juan Francisco, additional, Klein, Christophe, additional, Blanc-Durand, Félix, additional, Le Formal, Audrey, additional, Pujade-Lauraine, Eric, additional, Chardin, Laure, additional, Edmond, Elodie, additional, Marty, Virginie, additional, Ray-Coquard, Isabelle, additional, Joly, Florence, additional, Ferron, Gwenaël, additional, Pautier, Patricia, additional, Berton-Rigaud, Dominique, additional, Lortholary, Alain, additional, Dohollou, Nadine, additional, Desauw, Christophe, additional, Fabbro, Michel, additional, Malaurie, Emmanuelle, additional, Bonichon-Lamichhane, Nathalie, additional, Bello Roufai, Diana, additional, Gantzer, Justine, additional, Rouleau, Etienne, additional, Genestie, Catherine, additional, and Leary, Alexandra, additional

Published
2024
Full Text
View/download PDF

25. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Author

Monk, Bradley J, Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M, Karlan, Beth Y, Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L, Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Ma, Haijun, Vogl, Florian D, Bach, Bruce A, and Oza, Amit M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Ovarian Cancer, Clinical Research, Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Ascites, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Paclitaxel, Recombinant Fusion Proteins, Trebananib, TRINOVA-1, Recurrent epithelial ovarian cancer, Overall survival, Time to second disease progression, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

PurposeTrebananib, a peptibody that blocks binding of angiopoietin-1 and -2 to Tie2, significantly prolonged progression-free survival (PFS) in patients with recurrent epithelial ovarian cancer in the phase 3 TRINOVA-1 study. We report overall survival (OS) in the intent-to-treat population and clinically relevant subgroups and time to second disease progression (PFS-2).Patients and methodsWomen with recurrent disease (platinum-free interval

Published
2016

28. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome

Author

Scholl, Suzy, Popovic, Marina, de la Rochefordiere, Anne, Girard, Elodie, Dureau, Sylvain, Mandic, Aljosa, Koprivsek, Katarina, Samet, Nina, Craina, Marius, Margan, Madalin, Samuels, Sanne, Zijlmans, Henry, Kenter, Gemma, Hillemanns, Peter, Dema, Sorin, Dema, Alis, Malenkovic, Goran, Djuran, Branislav, Floquet, Anne, Garbay, Delphine, Guyon, Frédéric, Colombo, Pierre Emmanuel, Fabbro, Michel, Kerr, Christine, Ngo, Charlotte, Lecuru, Fabrice, Campo, Eleonor Rivin del, Coutant, Charles, Marchal, Frédéric, Mesgouez-Nebout, Nathalie, Fourchotte, Virginie, Feron, Jean Guillaume, Morice, Philippe, Deutsch, Eric, Wimberger, Pauline, Classe, Jean-Marc, Gleeson, Noreen, von der Leyen, Heiko, Minsat, Mathieu, Dubot, Coraline, Gestraud, Pierre, Kereszt, Attila, Nagy, Istvan, Balint, Balazs, Berns, Els, Jordanova, Ekaterina, Saint-Jorre, Nicolas de, Savignoni, Alexia, Servant, Nicolas, Hupe, Philippe, de Koning, Leanne, Fumoleau, Pierre, Rouzier, Roman, and Kamal, Maud

Published
2019
Full Text
View/download PDF

29. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

Author

Fabbro, Michel, Moore, Kathleen N., Dørum, Anne, Tinker, Anna V., Mahner, Sven, Bover, Isabel, Banerjee, Susana, Tognon, Germana, Goffin, Frederic, Shapira-Frommer, Ronnie, Wenham, Robert M., Hellman, Kristina, Provencher, Diane, Harter, Philipp, Vázquez, Isabel Palacio, Follana, Philippe, Pineda, Mario J., Mirza, Mansoor R., Hazard, Sebastien J., and Matulonis, Ursula A.

Published
2019
Full Text
View/download PDF

30. Anti-Angiopoietin Therapy With Trebananib for Recurrent Ovarian Cancer (TRINOVA-1)

Author

Monk, Bradley J, Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M, Karlan, Beth Y, Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L, Herzog, Thomas J, Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Tassoudji, Marjan, Navale, Lynn, Warner, Douglas J, and Oza, Amit M

Subjects
Clinical Trials and Supportive Activities, Rare Diseases, Ovarian Cancer, Patient Safety, Cancer, Clinical Research, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Published
2014

31. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

Author

Monk, Bradley J, Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M, Karlan, Beth Y, Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L, Herzog, Thomas J, Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Tassoudji, Marjan, Navale, Lynn, Warner, Douglas J, and Oza, Amit M

Subjects
Digestive Diseases, Clinical Trials and Supportive Activities, Ovarian Cancer, Rare Diseases, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Angiogenesis Inhibitors, Angiopoietin-1, Angiopoietin-2, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Ovarian Epithelial, Disease-Free Survival, Double-Blind Method, Edema, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Paclitaxel, Recombinant Fusion Proteins, Withholding Treatment, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAngiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to the Tie2 receptor, and thereby inhibits angiogenesis. We aimed to assess whether the addition of trebananib to single-agent weekly paclitaxel in patients with recurrent epithelial ovarian cancer improved progression-free survival.MethodsFor this randomised, double-blind phase 3 study undertaken between Nov 10, 2010, and Nov 19, 2012, we enrolled women with recurrent epithelial ovarian cancer from 32 countries. Patient eligibility criteria included having been treated with three or fewer previous regimens, and a platinum-free interval of less than 12 months. We enrolled patients with a computerised interactive voice response system, and patients were randomly assigned using a permuted block method (block size of four) in a 1:1 ratio to receive weekly intravenous paclitaxel (80 mg/m(2)) plus either weekly masked intravenous placebo or trebananib (15 mg/kg). Patients were stratified on the basis of platinum-free interval (≥0 and ≤6 months vs >6 and ≤12 months), presence or absence of measurable disease, and region (North America, western Europe and Australia, or rest of world). The sponsor, investigators, site staff, and patients were masked to the treatment assignment. The primary endpoint was progression-free survival assessed in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT01204749, and is no longer accruing patients.Findings919 patients were enrolled, of whom 461 were randomly assigned to the trebananib group and 458 to the placebo group. Median progression-free survival was significantly longer in the trebananib group than in the placebo group (7·2 months [5·8-7·4] vs 5·4 months [95% CI 4·3-5·5], respectively, hazard ratio 0·66, 95% CI 0·57-0·77, p

Published
2014

32. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial

Author

Romeo, Clémence, Joly, Florence, Ray-Coquard, Isabelle, El Kouri, Claude, Mercier-Blas, Anne, Berton-Rigaud, Dominique, Kalbacher, Elsa, Cojocarasu, Oana, Fabbro, Michel, Cretin, Jacques, Zannetti, Alain, Abadie-Lacourtoisie, Sophie, Mollon, Delphine, Hardy-Bessard, Anne-Claire, Provansal, Magali, Blot, Emmanuel, Delbaldo, Catherine, Lesoin, Anne, Freyer, Gilles, and You, Benoît

Published
2019
Full Text
View/download PDF

33. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Author

Lorusso, Domenica, primary, Mouret-Reynier, Marie-Ange, additional, Harter, Philipp, additional, Cropet, Claire, additional, Caballero, Cristina, additional, Wolfrum-Ristau, Pia, additional, Satoh, Toyomi, additional, Vergote, Ignace, additional, Parma, Gabriella, additional, Nøttrup, Trine J, additional, Lebreton, Coriolan, additional, Fasching, Peter A, additional, Pisano, Carmela, additional, Manso, Luis, additional, Bourgeois, Hugues, additional, Runnebaum, Ingo, additional, Zamagni, Claudio, additional, Hardy-Bessard, Anne-Claire, additional, Schnelzer, Andreas, additional, Fabbro, Michel, additional, Schmalfeldt, Barbara, additional, Berton, Dominique, additional, Belau, Antje, additional, Lotz, Jean-Pierre, additional, Gropp-Meier, Martina, additional, Gladieff, Laurence, additional, Lück, Hans-Joachim, additional, Abadie-Lacourtoisie, Sophie, additional, Pujade-Lauraine, Eric, additional, and Ray-Coquard, Isabelle, additional

Published
2023
Full Text
View/download PDF

34. Attentes des patientes suivies pour un cancer de l’ovaire concernant les traitements d’entretien : résultats de la cohorte française GINECO de l’enquête européenne NOGGO/ENGOT-ov22 (Expression IV)

Author

Lorcet, Marianne, Lortholary, Alain, Kurtz, Jean Emmanuel, Berton-Rigaud, Dominique, Fabbro, Michel, De La Motte Rouge, Thibault, Kaminsky-Forrett, Marie Christine, Floquet, Anne, Freyer, Gilles, Combe, Pierre, Dohollou, Nadine, Kalbacher, Elsa, Despax, Raymond, Largillier, Remy, Hardy Bessard, Anne Claire, Gane, Nicolas, Sehouli, Jalid, Oskay-Oezcelik, Guelten, Licaj, Idlir, Ray-Coquard, Isabelle, and Joly Lobbedez, Florence

Published
2018
Full Text
View/download PDF

35. Association of patterns of care, prognostic factors, and use of radiotherapy–temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study

Author

Fabbro-Peray, Pascale, Zouaoui, Sonia, Darlix, Amélie, Fabbro, Michel, Pallud, Johan, Rigau, Valérie, Mathieu-Daude, Hélène, Bessaoud, Faiza, Bauchet, Fabienne, Riondel, Adeline, Sorbets, Elodie, Charissoux, Marie, Amelot, Aymeric, Mandonnet, Emmanuel, Figarella-Branger, Dominique, Duffau, Hugues, Tretarre, Brigitte, Taillandier, Luc, and Bauchet, Luc

Published
2019
Full Text
View/download PDF

36. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

38. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author

Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary

Published
2023
Full Text
View/download PDF

40. PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Author

Grisham, Rachel, primary, Aghajanian, Carol, additional, Nieuwenhuysen, Els Van, additional, Rodrigues, Manuel, additional, Ring, Kari, additional, Santin, Alessandro, additional, Colombo, Nicoletta, additional, Prendergast, Emily, additional, Thaker, Premal, additional, Moore, Kathleen, additional, Salinas, Erin, additional, Ray-Coquard, Isabelle, additional, Chon, Hye Sook, additional, Rose, Peter, additional, Oaknin, Ana, additional, Clamp, Andrew, additional, Gandhi, Mitul, additional, Monk, Bradley, additional, Holloway, Robert, additional, Gorp, Toon Van, additional, Fabbro, Michel, additional, Gennigens, Christine, additional, Wojtynek, Nicholas, additional, Lustgarten, Stephanie, additional, and Banerjee, Susana, additional

Published
2023
Full Text
View/download PDF

41. Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer

Author

Vendrell, Julie A., primary, Ban, Iulian O., additional, Solassol, Isabelle, additional, Audran, Patricia, additional, Cabello-Aguilar, Simon, additional, Topart, Delphine, additional, Lindet-Bourgeois, Clothilde, additional, Colombo, Pierre-Emmanuel, additional, Legouffe, Eric, additional, D’Hondt, Véronique, additional, Fabbro, Michel, additional, and Solassol, Jérôme, additional

Published
2023
Full Text
View/download PDF

42. #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Author

Banerjee, Susana N, primary, Ring, Kari L, additional, Niewenhuysen, Els Van, additional, Fabbro, Michel, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Colombo, Nicoletta, additional, Santin, Alessandro D, additional, Clamp, Andrew R, additional, Moore, Kathleen N, additional, Rose, Peter G, additional, David M, O’Malley, additional, Chon, Hye Sook, additional, Salinas, Erin A, additional, Prendergast, Emily N, additional, Lustgarten, Stephanie, additional, Rodrigues, Manuel, additional, Gennigens, Christine, additional, Monk, Bradley J, additional, and Grisham, Rachel N, additional

Published
2023
Full Text
View/download PDF

43. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Author

Butowski, Nicholas, Campian, Jian, Recht, Lawrence, Lim, Michael, Ashby, Lynn, Drappatz, Jan, Hirte, Hal, Iwamoto, Fabio, Mechtler, Laszlo, Goldlust, Samuel, Becker, Kevin, Barnett, Gene, Nicholas, Garth, Desjardins, Annick, Benkers, Tara, Wagle, Naveed, Groves, Morris, Kesari, Santosh, Horvath, Zsolt, Merrell, Ryan, Curry, Richard, O'Rourke, James, Schuster, David, Wong, Mark, Mrugala, Maciej, Jensen, Randy, Trusheim, John, Lesser, Glenn, Belanger, Karl, Sloan, Andrew, Purow, Benjamin, Fink, Karen, Raizer, Jeffrey, Schulder, Michael, Nair, Suresh, Peak, Scott, Perry, James, Brandes, Alba, Weller, Michael, Mohile, Nimish, Landolfi, Joseph, Olson, Jon, Finocchiaro, Gaetano, Jennens, Ross, DeSouza, Paul, Robinson, Bridget, Crittenden, Marka, Shih, Kent, Flowers, Alexandra, Ong, Shirley, Connelly, Jennifer, Hadjipanayis, Costas, Giglio, Pierre, Mott, Frank, Mathieu, David, Lessard, Nathalie, Sepulveda, Sanchez Juan, Lövey, József, Wheeler, Helen, Inglis, Po-Ling, Hardie, Claire, Bota, Daniela, Lesniak, Maciej, Portnow, Jana, Frankel, Bruce, Junck, Larry, Thompson, Reid, Berk, Lawrence, McGhie, John, Macdonald, David, Saran, Frank, Soffietti, Riccardo, Blumenthal, Deborah, André de, Sá Barreto Costa Marcos, Nowak, Anna, Singhal, Nimit, Hottinger, Andreas, Schmid, Andrea, Srkalovic, Gordan, Baskin, David, Fadul, Camilo, Nabors, Louis, LaRocca, Renato, Villano, John, Paleologos, Nina, Kavan, Petr, Pitz, Marshall, Thiessen, Brian, Idbaih, Ahmed, Frenel, Jean Sébastien, Domont, Julien, Grauer, Oliver, Hau, Peter, Marosi, Christine, Sroubek, Jan, Hovey, Elizabeth, Sridhar, P.S., Cher, Lawrence, Dunbar, Erin, Coyle, Thomas, Raymond, Jane, Barton, Kevin, Guarino, Michael, Raval, Sumul, Stea, Baldassarre, Dietrich, Jorge, Hopkins, Kirsten, Erridge, Sara, Steinbach, Joachim-Peter, Pineda, Losada Estela, Balana, Quintero Carmen, Sonia del, Barco Berron, Wenczl, Miklós, Molnár, Katalin, Hideghéty, Katalin, Lossos, Alexander, Myra van, Linde, Levy, Ana, Harrup, Rosemary, Patterson, William, Lwin, Zarnie, Sathornsumetee, Sith, Lee, E-Jian, Ho, Jih-Tsun, Emmons, Steven, Duic, J. Paul, Shao, Spencer, Ashamalla, Hani, Weaver, Michael, Lutzky, Jose, Avgeropoulos, Nicholas, Hanna, Wahid, Nadipuram, Mukund, Cecchi, Gary, O'Donnell, Robert, Pannullo, Susan, Carney, Jennifer, Hamilton, Mark, MacNeil, Mary, Beaney, Ronald, Fabbro, Michel, Schnell, Oliver, Fietkau, Rainer, Stockhammer, Guenther, Malinova, Bela, Odrazka, Karel, Sames, Martin, Miguel Gil, Gil, Razis, Evangelia, Lavrenkov, Konstantin, Castro, Guillermo, Ramirez, Francisco, Baldotto, Clarissa, Viola, Fabiana, Malheiros, Suzana, Lickliter, Jason, Gauden, Stanislaw, Dechaphunkul, Arunee, Thaipisuttikul, Iyavut, Thotathil, Ziad, Ma, Hsin-I, Cheng, Wen-Yu, Chang, Chin-Hong, Salas, Fernando, Dietrich, Pierre-Yves, Mamot, Christoph, Nayak, Lakshmi, Nag, Shona, Tran, David D, Recht, Lawrence D, Goldlust, Samuel A, O'Rourke, Donald M, Hamilton, Mark G, Wick, Wolfgang, Green, Jennifer, He, Yi, Turner, Christopher D, Yellin, Michael J, Keler, Tibor, Davis, Thomas A, Stupp, Roger, and Sampson, John H

Published
2017
Full Text
View/download PDF

44. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF)

Author

Lebellec, Loïc, Chauffert, Bruno, Blay, Jean-Yves, Le Cesne, Axel, Chevreau, Christine, Bompas, Emmanuelle, Bertucci, François, Cupissol, Didier, Fabbro, Michel, Saada-Bouzid, Esma, Duffaud, Florence, Feuvret, Loïc, Bonneville-Levard, Alice, Bay, Jacques-Olivier, Vauleon, Elodie, Vinceneux, Armelle, Noel, Georges, Penel, Nicolas, and Mir, Olivier

Published
2017
Full Text
View/download PDF

45. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study

Author

Houillier, Caroline, Soussain, Carole, Ghesquières, Hervé, Soubeyran, Pierre, Chinot, Olivier, Taillandier, Luc, Lamy, Thierry, Choquet, Sylvain, Ahle, Guido, Damaj, Gandhi, Agapé, Philippe, Moluçon-Chabrot, Cécile, Amiel, Alexandra, Delwail, Vincent, Fabbro, Michel, Jardin, Fabrice, Chauchet, Adrien, Moles-Moreau, Marie-Pierre, Morschhauser, Franck, Casasnovas, Olivier, Gressin, Rémy, Fornecker, Luc-Matthieu, Abraham, Julie, Marolleau, Jean-Pierre, Tempescul, Adrian, Campello, Chantal, Colin, Philippe, Tamburini, Jérôme, Laribi, Kamel, Serrier, Caroline, Haioun, Corinne, Chebrek, Safia, Schmitt, Anna, Blonski, Marie, Houot, Roch, Boyle, Eileen, Bay, Jacques-Olivier, Oberic, Lucie, Tabouret, Emeline, Waultier, Agathe, Martin-Duverneuil, Nadine, Touitou, Valérie, Cassoux, Nathalie, Kas, Aurélie, Mokhtari, Karima, Charlotte, Frederic, Alentorn, Agusti, Feuvret, Loïc, Le Garff-Tavernier, Magali, Costopoulos, Myrto, Mathon, Bertrand, Peyre, Matthieu, Delgadillo, Daniel, Douzane, Hassen, Genet, Diane, Aidaoui, Bachir, Hoang-Xuan, Khê, and Gyan, Emmanuel

Published
2020
Full Text
View/download PDF

46. Corrigendum to “A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer”

Author

Blanc-Durand, Félix, primary, Yaniz-Galende, Elisa, additional, Llop-Guevara, Alba, additional, Genestie, Catherine, additional, Serra, Violeta, additional, Herencia-Ropero, Andrea, additional, Klein, Christophe, additional, Berton, Dominique, additional, Lortholary, Alain, additional, Dohollou, Nadine, additional, Desauw, Christophe, additional, Fabbro, Michel, additional, Malaurie, Emmanuelle, additional, Bonichon-Lamaichhane, Nathalie, additional, Dubot, Coraline, additional, Kurtz, Jean Emmanuel, additional, de Rauglaudre, Gaëtan, additional, Raban, Nadia, additional, Chevalier-Place, Annick, additional, Ferron, Gwenael, additional, Kaminsky, Marie-Christine, additional, Kramer, Claire, additional, Rouleau, Etienne, additional, and Leary, Alexandra, additional

Published
2023
Full Text
View/download PDF

49. Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study

Author

Nowosielski, Martha, Gorlia, Thierry, Bromberg, Jacoline E.C., Sahm, Felix, Harting, Inga, Kickingereder, Philipp, Brandes, Alba A., Taphoorn, Martin J.B., Taal, Walter, Domont, Julien, Idbaih, Ahmed, Campone, Mario, Clement, Paul M., Weller, Michael, Fabbro, Michel, Le Rhun, Emilie, Platten, Michael, Golfinopoulos, Vassilis, van den Bent, Martin J., Bendszus, Martin, and Wick, Wolfgang

Published
2019
Full Text
View/download PDF

50. HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.

Author

Fabbro, Michel, Lamy, Pierre-Jean, Touraine, Célia, Floquet, Anne, Ray-Coquard, Isabelle, and Mollevi, Caroline

Subjects
CLINICAL trials, PROGRESSION-free survival, PROGNOSIS, OVARIAN epithelial cancer, MULTIVARIATE analysis, MEDICAL screening, OVARIAN cancer
Abstract

HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC. Serum samples were prospectively collected before the first chemotherapy cycle and every 3 months until disease progression. Data from 89/101 patients could be analyzed. At baseline, the median CA-125 and HE4 concentrations were 210 IU/L (7-10,310) and 184 pM (31-4,836). Among the 12 patients (13%) with normal CA-125 (<35 IU/L) concentration, eight had HE4 concentration ≥75 pM, and among the 16 patients with normal HE4 concentration (18%), 12 had increased CA-125 concentration. The median nadir concentrations were 31 IU/L (3-8,744) for CA-125 and 75 pM (20-4,836) for HE4. The median times to nadir were 14 (0-130) weeks for CA- 125 and 12 (0-52) weeks for HE4. In multivariate analysis, CA-125 and HE4 nadir concentrations (<35 IU/L, HR 0.35, 95% CI: 0.17-0.72 and<75 pM, HR 0.40, 95% CI: 0.20-0.79) and time to CA-125 and HE4 nadir (>14 weeks, HR 0.37, 95% CI: 0.20-0.70 and >12 weeks, HR 0.43, 95% CI: 0.23-0.83) were prognostic factors of progression-free survival. More investigations on HE4 kinetics could help to better monitor patients with CA-125 concentration within normal values. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results